Why choose DUROLANE?

The original single injection for osteoarthritis pain relief, since 2001*.

Advanced and unique NASHA technology ⁸
History of safe use ⁹
Longer lasting by design ^8,10
Significant and sustained benefits for OA patients ^11,12,13

*First introduced in the European Union in 2001

Summary of Indications for Use
DUROLANE (3 mL): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

DUROLANE SJ (1 mL): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes.

Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.

There are no known contraindications.

You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children.

Risks can include transient pain, swelling and/or stiffness at the injection site.

Full prescribing information can be found in product labeling.

DUROLANE, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. NASHA is a registered trademark of Nestlé Skin Health S.A.

© 2017. Bioventus LLC.

^{*First introduced in the European Union in 2001.}

To learn more about DUROLANE or for contact information, please select your location to continue.